Literature DB >> 26232077

Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains.

Verônica M Saia-Cereda1, Juliana S Cassoli1, Andrea Schmitt2,3, Peter Falkai3, Juliana M Nascimento1,4, Daniel Martins-de-Souza5,6,7.   

Abstract

Schizophrenia is an incurable and debilitating mental disorder that may affect up to 1% of the world population. Morphological, electrophysiological, and neurophysiological studies suggest that the corpus callosum (CC), which is the largest portion of white matter in the human brain and responsible for inter-hemispheric communication, is altered in schizophrenia patients. Here, we employed mass spectrometry-based proteomics to investigate the molecular underpinnings of schizophrenia. Brain tissue samples were collected postmortem from nine schizophrenia patients and seven controls at the University of Heidelberg, Germany. Because the CC has a signaling role, we collected cytoplasmic (soluble) proteins and submitted them to nano-liquid chromatography-mass spectrometry (nano LC-MS/MS). Proteomes were quantified by label-free spectral counting. We identified 5678 unique peptides that corresponded to 1636 proteins belonging to 1512 protein families. Of those proteins, 65 differed significantly in expression: 28 were upregulated and 37 downregulated. Our data increased significantly the knowledge derived from an earlier proteomic study of the CC. Among the differentially expressed proteins are those associated with cell growth and maintenance, such as neurofilaments and tubulins; cell communication and signaling, such as 14-3-3 proteins; and oligodendrocyte function, such as myelin basic protein and myelin-oligodendrocyte glycoprotein. Additionally, 30 of the differentially expressed proteins were found previously in other proteomic studies in postmortem brains; this overlap in findings validates the present study and indicates that these proteins may be markers consistently associated with schizophrenia. Our findings increase the understanding of schizophrenia pathophysiology and may serve as a foundation for further treatment strategies.

Entities:  

Keywords:  Corpus callosum; Mass spectrometry; Postmortem brain; Proteome; Proteomics; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26232077     DOI: 10.1007/s00406-015-0621-1

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  65 in total

Review 1.  14-3-3 proteins in the nervous system.

Authors:  Daniela Berg; Carsten Holzmann; Olaf Riess
Journal:  Nat Rev Neurosci       Date:  2003-09       Impact factor: 34.870

Review 2.  Schizophrenia.

Authors:  Robert Freedman
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

3.  Transmission disequilibrium analysis of the GSN gene in a cohort of family trios with schizophrenia.

Authors:  Z R Xi; W Qin; Y F Yang; G He; S H Gao; M S Ren; Y W Peng; Z Zhang; L He
Journal:  Neurosci Lett       Date:  2004-12-06       Impact factor: 3.046

Review 4.  Which way to go? Cytoskeletal organization and polarized transport in neurons.

Authors:  Lukas C Kapitein; Casper C Hoogenraad
Journal:  Mol Cell Neurosci       Date:  2010-09-09       Impact factor: 4.314

5.  Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: potential roles in GABAergic interneuron pathology.

Authors:  Klaus Oliver Schubert; Melanie Föcking; David R Cotter
Journal:  Schizophr Res       Date:  2015-02-23       Impact factor: 4.939

6.  2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia.

Authors:  Sudhakaran Prabakaran; Martina Wengenroth; Helen E Lockstone; Kathryn Lilley; F Markus Leweke; Sabine Bahn
Journal:  J Proteome Res       Date:  2007-01       Impact factor: 4.466

7.  Enzymes of the antioxidant defense system in chronic schizophrenic patients.

Authors:  R Reddy; M P Sahebarao; S Mukherjee; J N Murthy
Journal:  Biol Psychiatry       Date:  1991-08-15       Impact factor: 13.382

8.  Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia.

Authors:  Daniel Martins-de-Souza; Giuseppina Maccarrone; Thomas Wobrock; Inga Zerr; Philipp Gormanns; Stefan Reckow; Peter Falkai; Andrea Schmitt; Christoph W Turck
Journal:  J Psychiatr Res       Date:  2010-05-14       Impact factor: 4.791

Review 9.  Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications.

Authors:  Ashwini Rajasekaran; Ganesan Venkatasubramanian; Michael Berk; Monojit Debnath
Journal:  Neurosci Biobehav Rev       Date:  2014-11-15       Impact factor: 8.989

10.  Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Lian Yuan Cao; Pei Yan Zhang; Gui Ying Wu
Journal:  Psychiatry Res       Date:  2003-01-25       Impact factor: 3.222

View more
  26 in total

1.  Negative symptoms and therapy strategies in schizophrenia.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-10       Impact factor: 5.270

2.  Increased density of DISC1-immunoreactive oligodendroglial cells in fronto-parietal white matter of patients with paranoid schizophrenia.

Authors:  Hans-Gert Bernstein; Esther Jauch; Henrik Dobrowolny; Christian Mawrin; Johann Steiner; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-28       Impact factor: 5.270

3.  Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders.

Authors:  André S L M Antunes; Valéria de Almeida; Fernanda Crunfli; Victor C Carregari; Daniel Martins-de-Souza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Extracellular matrix proteomics in schizophrenia and Alzheimer's disease.

Authors:  Manveen K Sethi; Joseph Zaia
Journal:  Anal Bioanal Chem       Date:  2016-09-06       Impact factor: 4.142

5.  The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains.

Authors:  Verônica M Saia-Cereda; Aline G Santana; Andrea Schmitt; Peter Falkai; Daniel Martins-de-Souza
Journal:  Mol Neuropsychiatry       Date:  2017-06-17

6.  Molecular Features Triggered by Antipsychotic Medication in Brain Cells.

Authors:  Lívia Ramos-da-Silva; André S L M Antunes
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

7.  Proteomics and Schizophrenia: The Evolution of a Great Partnership.

Authors:  Bradley J Smith; Victor C Carregari; Daniel Martins-de-Souza
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

8.  Disruption of microglia histone acetylation and protein pathways in mice exhibiting inflammation-associated depression-like symptoms.

Authors:  Sandra L Rodriguez-Zas; Cong Wu; Bruce R Southey; Jason C O'Connor; Scott E Nixon; Robmay Garcia; Cynthia Zavala; Marcus Lawson; Robert H McCusker; Elena V Romanova; Jonathan V Sweedler; Keith W Kelley; Robert Dantzer
Journal:  Psychoneuroendocrinology       Date:  2018-06-30       Impact factor: 4.905

9.  Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots.

Authors:  Jason D Cooper; Sureyya Ozcan; Renee M Gardner; Nitin Rustogi; Susanne Wicks; Geertje F van Rees; F Markus Leweke; Christina Dalman; Håkan Karlsson; Sabine Bahn
Journal:  Transl Psychiatry       Date:  2017-12-18       Impact factor: 6.222

Review 10.  Psychiatric disorders biochemical pathways unraveled by human brain proteomics.

Authors:  Verônica M Saia-Cereda; Juliana S Cassoli; Daniel Martins-de-Souza; Juliana M Nascimento
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-07-04       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.